S99 Upadacitinib in the Treatment of Ulcerative Colitis. Initial Real-World Experience From a Tertiary Care Center

improvement was observed in 12 (70.5%) patients. Amongst the 5 cases that did not respond, 3 cases had primary sclerosing cholangitis, 1 underwent colectomy and colectomy is being considered in 2 cases. There were no adverse e ﬀ ects reported with Upadacitinib use. Conclusion(s): In a single center cohort of 23 patients with UC refractory to anti-TNF-a, upada- citinib use resulted in clinical improvement in 70% of patients with no adverse events. Further long-term data is being collected.